Stefani S, Russo G, Nicolosi V M, Nicoletti G
Chemioterapia. 1987 Feb;6(1):12-6.
Some clinical isolates of enterococci were tested for susceptibility to gentamicin, tobramycin, amikacin and netilmicin. Five percent of Streptococcus faecalis tested demonstrated high level resistance (minimum inhibitory concentration (MIC) greater than 2024 micrograms/ml) to gentamicin, tobramycin and netilmicin, while amikacin had MICs greater than 128 micrograms/ml for all strains tested. Since a combination of a beta-lactam and streptomycin does not produce synergism against all strains of enterococci for an increase in the number of highly resistant strains, the effect of piperacillin plus gentamicin, tobramycin, and netilmicin was examined. The combination piperacillin + netilmicin seemed to be very effective against all enterococci tested.
对一些肠球菌临床分离株进行了庆大霉素、妥布霉素、阿米卡星和奈替米星的药敏试验。粪链球菌检测结果显示,5%的菌株对庆大霉素、妥布霉素和奈替米星表现出高水平耐药(最低抑菌浓度(MIC)大于2024微克/毫升),而所有受试菌株对阿米卡星的MIC均大于128微克/毫升。由于β-内酰胺类与链霉素联合使用对所有肠球菌菌株不会产生协同作用,且高耐药菌株数量增加,因此研究了哌拉西林加庆大霉素、妥布霉素和奈替米星的效果。哌拉西林+奈替米星联合用药似乎对所有受试肠球菌都非常有效。